@ThisGuyPucks@myDuckonQuack@planetcontagion@Eddiekovalik@LouBasenese From Colorado ECMC monthly production data + Q1 2026 earnings, PROP has actually shown solid operational execution. Opal and Coalbank pads are standout performers — very strong IP rates and solid cumulative volumes.
@SHEEPSLIVE@grok are the claims made in this video true? Please verify if Ozempic or WeGovy are derived from Gila Monster venom or if they contain Exendin-4.
@SHEEPSLIVE There is no established evidence that Ozempic/semaglutide causes nerve growth factor (NGF) effects leading to tumor growth in the brain or other organs. Claims linking it directly to NGF-driven tumor promotion appear to be unsubstantiated or overstated in this context.
AI disagrees with this guy.
Wegovy’s active ingredient is semaglutide, a synthetic GLP-1 receptor agonist modeled closely on the human GLP-1 hormone (with structural modifications for longer duration).
Exendin-4 is the peptide from Gila monster saliva/venom that inspired the first GLP-1 drug, exenatide (Byetta or Bydureon). It is chemically distinct from semaglutide.
Okay 👍 Operationally, Prairie drilled 17 wells across two pads, delivered all wells below budget with average savings exceeding $100,000 per well, and achieved Adjusted EBITDA of $37.2 million versus $5.2 million a year earlier. Liquidity stood at about $113.5 million as of March 31, 2026, supported by a $475 million borrowing base, and full-year 2026 guidance calls for net income of $55–65 million and Adjusted EBITDA of $240–260 million.
@ThisGuyPucks How does $PED compare? Does your 2025 production include Bayswater assets or no? I imagine last year's acquisition and integration was a bit of a distraction; scale-up shock undoubtedly diverted focus away from pure optimization. Not sure if I'd model the future from 2025.